Search Videos and More
News
Fox Chase – Temple Urologic Institute’s Jennifer Kelly Becomes First Temple Health Nurse to Earn Certification From Society of Urologic Nurses & Associates
Jennifer Kelly, BSN, RN, CURN, a nurse with the Fox Chase-Temple Urologic Institute, has become the first nurse in the Temple Health system to earn certification from the Society of Urologic Nurses & Associates (SUNA).
News
Newer Radiation Technique Reduces Side Effects While Maintaining Effectiveness
Researchers at Fox Chase Cancer Center have demonstrated that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce side effects while maintaining treatment effectiveness for patients with esophageal cancer and non-small cell lung cancer.
Video
Beyond the Routine – Adapt or Not?
Challenges and Dilemmas in Adaptive Radiation Treatment Planning
News
Adaptive Radiation Therapy Increases Safety and Preserves Quality of Life, Says Study
For patients with recurrent retroperitoneal sarcomas that cannot be treated surgically, treatment choices are limited. These tumors can grow quite large in the abdomen adjacent to vital organs or enmeshed within the bowel.
News
Fox Chase Cancer Center’s Dr. Joshua E. Meyer Named a Fellow of the American Society for Radiation Oncology
Joshua E. Meyer, MD, FASTRO, Vice Chair of Translational Research and a Professor in the Department of Radiation Oncology at Fox Chase Cancer Center, has been named a Fellow of the American Society for Radiation Oncology (ASTRO) at the organization’s 2025 Annual Meeting being held in San Francisco.
News
Temple Health and Fox Chase Cancer Center Surgeon Dr. Jay Simhan Receives First-Place Award at Annual Jackson Hole Seminar Series in Urology
Jay Simhan, MD, FACS, Chair of the Department of Urology at Temple University Hospital and the Lewis Katz School of Medicine at Temple University, and Director of Reconstruction at Fox Chase Cancer Center, was awarded first place at the 44th Annual Ralph E. Hopkins Jackson Hole Seminar Series in Urology.
News
A RACE AGAINST TIME AND DISEASE
“We’ve made great strides treating melanoma at Fox Chase and have built one of the most comprehensive multidisciplinary teams in the region—an expertise recognized nationally and internationally,” says Jeffrey M. Farma, MD, FACS, Chair and Professor, Department of Surgery, Fox Chase Cancer Center. “I’m thrilled to bring TIL (tumor-infiltrating lymphocyte) therapy to our metastatic melanoma patients who are not responding to their first-line treatment—a cellular therapy which requires critical timing and a highly specialized multidisciplinary team to deliver it.”
News
Aiming to Refine NSCLC Targeted Therapy
The first study to prospectively examine the impact of co-mutation biomarkers on sotorasib, a novel targeted therapy, for advanced KRAS G12C mutated NSCLC
News
Fox Chase Cancer Center Researcher Secures Funding to Investigate Toxicity Reduction in Bladder Cancer Treatment
Pooja Ghatalia, MD, Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, developed a trial to administer therapy for metastatic urothelial carcinoma patients in a new way. The Department of Defense awarded Ghatalia a $1.9 million grant to pursue the research, making it one of only five chosen out of 51 studies.
News
A Life-Extending Study for Colorectal Cancer Patients with Inoperable Liver Metastases
Physicians at Fox Chase Cancer Center have begun accepting patients for a new clinical trial looking at the effectiveness of a hepatic artery infusion (HAI) pump along with standard chemotherapy. Fox Chase is the only local hospital offering this trial, which is designed for patients with colorectal cancer that has spread to the liver and cannot be treated with surgery.
News
Forward Celebrates Fox Chase's 50 Years
Join us on a journey that commemorates the golden anniversary of Fox Chase Cancer Center. Learn about our milestones and achievements that have changed the world of cancer care. Meet the extraordinary clinicians and researchers who made it happen.
News
ASTRO 2025 Speaker and Poster Sessions
We welcome you to stop by Booth #2310 to connect with our team and learn more about our latest offerings and initiatives